Coming Off a GLP-1: What the Research Says About Weight, Muscle, and Planning Ahead
Many people eventually reduce or stop a GLP-1 medication, because of cost, side effects, reaching a goal, or a change in plans. The research on what happens next is sobering but not hopeless, and the best time to prepare is before you stop.
What the trials found
Semaglutide. In the STEP 1 extension, people averaged a 17.3% weight loss after 68 weeks on treatment. A year after stopping, they had regained about 11.6 percentage points, leaving a net loss of 5.6%. That's roughly two-thirds of the weight back.9
Tirzepatide. In SURMOUNT-4, people lost an average of about 21% over a 36-week lead-in. Those who then switched to placebo regained about 14% of their body weight over the next year, while those who continued treatment lost a further 5.5%.10
Pooled data. A 2026 meta-analysis of 37 studies found regain of roughly 0.8 kg (1.75 lb) per month after stopping either drug.11
What the trials don't tell us
These studies stopped treatment abruptly and gave participants no maintenance plan, so they show what happens without a strategy, not what's inevitable. Real-world data can look different. In a Cleveland Clinic cohort of 7,938 patients who stopped after 3 to 12 months, those treated for obesity (who had lost 8.4% on average) regained an average of just 0.5% a year later. That group lost less weight and was treated for less time than the trial participants, so it isn't a like-for-like comparison.12
Where muscle fits
We're not aware of trial evidence showing that keeping muscle prevents regain, so we won't promise that. Strength and physical function are worth protecting on their own, and the habits that protect them are the same ones that make any transition easier.
What to do
1. Talk to your prescriber before you stop or reduce. Ask about tapering or maintenance options, and agree in advance on what you'll do if weight starts climbing.
2. Keep protein steady. The same 1.2 to 1.6 g per kg of healthy body weight guidance applies, spread across meals.1,2
3. Keep lifting. Resistance work 2 to 3 times a week is the usual guidance, and bands count.8
4. Plan for appetite to come back. Protein-first plates and pre-planned meals take some of the decision-making out of it.
Biocare2
Robard, the company behind Biocare, launched Biocare2 as a companion for the transition phase. It describes it as a beverage for people reducing, microdosing, or discontinuing GLP-1 therapy, with 30g of protein plus fiber, probiotics, creatine, and botanical ingredients.13
That's the manufacturer's description. We haven't seen independent evidence that it affects appetite or regain, so treat it as a convenient high-protein shake for this phase, not a treatment. For the active-treatment version, see our Biocare review.
1. Joint advisory on nutrition for GLP-1 therapy (2025)
2. Healio report on the advisory's protein recommendation
8. UK consensus statement on GLP-1 and muscle preservation (2025)
9. STEP 1 extension, semaglutide withdrawal
10. SURMOUNT-4, tirzepatide withdrawal
11. 2026 meta-analysis of weight regain after stopping
12. Cleveland Clinic cohort of patients who stopped
13. Robard Biocare2 launch and product listing